The release highlights progress on AUTO3, a CAR T cell therapy being investigated in a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma (DLBCL), a cancer that starts in white blood cells.
“The data support a best in class profile with a high level of complete remissions and a well tolerated safety profile,” said Dr. Christian Itin, chairman and chief executive officer of Autolus.
“AUTO3 has a tolerable and very favorable safety profile when compared with approved CD19 CAR T therapies,” added Dr Craig Moskowitz, Professor of Medicine at Miller School of Medicine, University of Miami Health System.
“It has a promising complete response rate of 64%, as demonstrated in the completed cohorts at the recommended Phase 2 dose range and, thus far, these complete remissions also appear durable.
Autolus issued the data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 that started on 18 September.
DLBCL is the most common form of non-Hodgkin lymphoma among adults.